Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and used thereof
AssigneeLudwig Institute for Cancer Research
InventorsLaure Dumoutier, Jamila Louahed, Jean-Christophe Renauld
Life of this patent
Estimating the term…
Abstract
The invention involves isolation of nucleic acid molecules, the expression of which are upregulated by interleukin-9. The amino acid sequences of the proteins which correspond to the nucleic acid molecules show some structural features of cytokines. In addition to the nucleic acid molecules and the proteins, various uses of the molecules are disclosed. The molecules are referred to as T cell inducible factors.
Claims49
An isolated nucleic acid molecule which encodes a T cell derived inducible factor, the complementary sequence of which hybridizes, under stringent conditions, to at least one of SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:29, SEQ ID NO:
- 24 or SEQ ID NO:25.
A method for determining effectiveness of interleukin-9 on a cell, comprising contacting said cell with an agent specific for at least one of (i) an isolated nucleic acid molecule which encodes a protein whose amino acid sequence is identical to the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:29, SEQ ID NO:
- 24 or SEQ ID NO:
- 25 and (ii) a protein whose amino acid sequence is identical to the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:29,SEQ ID NO:
- 24 or SEQ ID NO:25 and determining interaction of said agent with (i) or (ii) as a determination of effectiveness of interleukin-9 on said cell.
A method for determining presence of TIF in a sample, comprising contacting said sample with an agent which binds to TIF or a nucleic acid molecule encoding TIF, and determining said binding as a determination of TIF in said sample.
A method for screening to determine if a substance influences IL-9 activity, comprising adding said substance to a sample of TIF producing cells, in the presence of IL-9, and determining production of TIF, wherein a difference in production of TIF by said cells as compared to production of TIF by said cells in presence of IL-9 but not said substance indicates said substance influences IL-9 activity.
A method for determining an aberrant level of IL-9 activity in a subject, comprising determining level of TIF in a subject and comparing said level to a normal level, differences therebetween being indicative of an aberrant level of IL-9 in said subject.
A method for inhibiting IL-9 induced activity in a subject in need thereof, comprising administering an amount of a TIF inhibitor sufficient to inhibit IL-9 induced activity.
A method for treating a subject suffering from asthma or an allergy, comprising administering to said subject an amount of a TIF mutein sufficient to alleviate said asthma or allergy.
A method for determining if a mutein of TIF is therapeutically useful, comprising contacting a cell which produces IL-9 with said mutein, and determining effect of said mutein on prouction of IL-9, reduction thereof being indicative of possible thereapeutic efficacy for said mutein.
A method for determining susceptibility to a condition characterized by aberrant expression of TIF, comprising determining nucleotide sequence of a TIF gene of a subject believed to possess an aberrant TIF gene, presence of an aberrant TIF gene being indicative of possible susceptibility to asthma or allergy.
Dependencies are inferred from the claim text.